[1]
|
Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold and J. M. Friedman, “Positional Cloning of the Mouse Obese Gene and Its Human Homologue,” Nature, Vol. 372, No. 6505, 1994, pp. 425-432. doi:10.1038/372425a0
|
[2]
|
C. Popa, M. G. Netea, T. Radstake, P. L. Van Riel, P. Barrera and J. W. M. Van Der Meer, “Markers of Inflammation Are Negatively Correlated with Serum Leptin in Rheumatoid Arthritis,” Annals of Rheumatic Diseases, Vol. 64, No. 8, 2005, pp. 1195-1198.
|
[3]
|
G. Matarese, S. Moschos and C. S. Mantzoros, “Leptin in Immunology,” Journal of Immunology, Vol. 174, No. 6, 2005, pp. 3137-3142.
|
[4]
|
M. R. Ram and R. Malathi, “Possible Correlation of Leptin with Body Fat Distribution and Adiposity: Evaluation of Serum Leptin in South Indian Population,” Reproductive Medicine and Biology, Vol. 6, No. 2, 2007, pp. 117-125. doi:10.1111/j.1447-0578.2007.00174.x
|
[5]
|
S. Loffreda, S. Q. Yang, H. Z. Lin, C. L. Karp, M. L. Brengman, D. J. Wang, A. S. Klein, G. B. Bulkley, C. Bao, P. W. Noble, M. D. Lane and A. M. Diehl, “Leptin Regulates Proinflammatory Immune Responses,” The Journal of the Federation of American Society for Experimental Biology, Vol. 12, No. 1, 1998, pp. 57-65.
|
[6]
|
J. V. Castell, M. J. Gomez-Lechon, M. David, R. Fabra, R. Trullenque and P. C. Heinrich, “Acute Phase Response of Human Hepatocytes: Regulation of Acute Phase Protein Synthesis by Interleukin-6,” Hepatology, Vol. 12, No. 5, 1990, pp. 1179-1186. doi:10.1002/hep.1840120517
|
[7]
|
P. Libby and P. M. Ridker, “Inflammation and Atherosclerosis: Role of C-Reactive Protein in Risk Assessment,” American Journal of Medicine, Vol. 116, No. 6, 2004, pp. 9-16. doi:10.1016/j.amjmed.2004.02.006
|
[8]
|
M. B. Pepys and G. M. Hirschfield, “C-Reactive Protein and Its Role in the Pathogenesis of Myocardial Infarction,” Italian Heart Journal, Vol. 2, No. 11, 2001, pp. 804-806.
|
[9]
|
L. Dubey, H.-S. Zeng, H.-J. Wang and R.-Y. Liu, “Potential Role of Adipocytokine Leptin in Acute Coronary Syndrome,” Asian Cardiovascular and Thoracic Annals, Vol. 16, No. 2, 2008, pp. 124-128
|
[10]
|
H. D. Sesso, J. E. Buring, N. Rifai, G. J. Blake, J. M. Gaziano and P. M. Ridker, “C-Reactive Protein and the Risk of Developing Hypertension,” Journal of American Medical Association, Vol. 290, No. 22, 2003, pp. 2945-2951. doi:10.1001/jama.290.22.2945
|
[11]
|
L. A. Viikari, R. K. Huupponen, J. S. A. Viikari, J. Marniemi, C. Eklund, M. Hurme, T. Lehtimaki, M. Kivimaki and O. T. Raitakari, “Relationship between Leptin and CReactive Protein in Young Finnish Adults,” The Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 12, 2007, pp. 4753-4758. doi:10.1210/jc.2007-0103
|
[12]
|
P. Trinder, “Determination of Blood Glucose Using 4Aminophenazone,” J Clin Pathol, Vol. 22, No. 2, 1959, p. 246. doi:10.1136/jcp.22.2.246-b
|
[13]
|
J. L. Beamount, L. A. Crison, G. R. Coope, Z. Feifar, D. S. Frederickson and T. Strasser, “Classification of Hyperlipidemias and Hyperlipoproteinemias,” Standard Methods of Clinical Chemistry, Academic Press, New York, 1972, p. 9.
|
[14]
|
D. N. Holvey, “The Merck Manual of Diagnosis and Therapy,” Merck Inc., Rahway, 1972.
|
[15]
|
T. G. Cole, S. G. Klotzsch and J. Mc Namara, “Measurement of Triglyceride Concentration. Handbook of Lipoprotein Testing,” AACC Press, Washington DC, 1997.
|
[16]
|
Z. X. Wang and T. Nakayama, “Inflammation, A Link between Obesity and Cardiovascular Disease,” Mediators of Inflammation, Vol. 2010, 2010, pp. 1-17.
doi:10.1155/2010/535918
|
[17]
|
W. A. Banks, A. B. Coon, S. M. Robinson, A. Moinuddin, J. M. Shultz, R. Nakaoke and J. E. Morley, “Triglycerides Induce Leptin Resistance at the Blood-Brain Barrier,” Diabetes, Vol. 53, No. 5, 2004, pp. 1253-1260.
doi:10.2337/diabetes.53.5.1253
|
[18]
|
J. M. Harkins, N. Moustaid-Moussa, Y.-J. Chung, K. M. Penner, J. J. Pestka, C. M. North and K. J. Claycomb, “Expression of Interleukin-6 Is Greater in Preadipocytes than in Adipocytes of 3T3-L1 Cells and C57BL/6J and ob/ob Mice,” Journal of Nutrirtion, Vol. 134, No. 10, 2004, pp. 2673-2677.
|
[19]
|
A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring and P. M. Ridker, “C-Reactive Protein, Interleukin-6, and Risk of Developing Type II Diabetes Mellitus,” Journal of American Medical Association, Vol. 286, No. 17, 2001, pp. 327-334. doi:10.1001/jama.286.3.327
|
[20]
|
M. Fasshauer, J. Klein, U. Lossner and R. Paschke, “Interleukin (IL)-6 mRNA Expression Is Stimulated by Insulin, Isoproterenol, Tumour Necrosis Factor Alpha, Growth Hormone, and IL-6 in 3T3-L1 Adipocytes,” Hormone and Metabolic Research, Vol. 35, No. 3, 2003, pp. 147-152. doi:10.1055/s-2003-39075
|
[21]
|
H. P. Kopp, C. W. Kopp, A. Festa, K. Krzyzanowska, S. Kriwanek, E. Minar, R. Roka and G. Schernthaner, “Impact of Weight Loss on Inflammatory Proteins and Their Association with the Insulin Resistance Syndrome in Morbidly Obese Patients,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 23, No. 6, 2003, pp. 1042-1047. doi:10.1161/01.ATV.0000073313.16135.21
|
[22]
|
L. Roytblat, M. Rachinsky, A. Fisher, L. Greemberg, Y. Shapira, A. Douvdevani and S. Gelman, “Raised Interleukin-6 Levels in Obese Patients,” Obesity Research, Vol. 8, 9, 2000, pp. 673-675. doi:10.1038/oby.2000.86
|
[23]
|
M. Laimer, C. F. Ebenbichler, S. Kaser, et al., “Markers of Chronic Inflammation and Obesity: A Prospective Study on the Reversibility of This Association in Middle-Aged Women Undergoing Weight Loss by Surgical Intervention,” International Journal of Obesity Related Metabolic Disorders, Vol. 26, No. 5, 2002, pp. 659-662.
doi:10.1038/sj.ijo.0801970
|
[24]
|
J. Li, F. H. Li and A. Zha, “Inflammation and Leptin,” Drug Discovery Today, Vol. 3, No. 3, 2006, pp. 387-393.
doi:10.1016/j.ddmec.2006.09.003
|